Summary-The combined effect of the chemotherapeutic agent ICRF-159 and irradiation were evaluated using the Lewis lung tumour (LL). At a daily dose of 25 mg/kg, ICOF given alone prevented the progressive growth of LL. Daily pretreatment also potentiated the effects of radiation (600 rad) on tumour growth, provided the pretreatment kinetics of the tumour permitted a response to radiation alone. Single acute doses of the drug failed to alter the growth of LL, and when combined with radiation failed to enhance the radiation effect. Fractionation of the drug (25 mg/kg; 4 doses at 3h intervals) before irradiation, however, results in immediate effects on tumour growth which are more than additive. The results suggest that a low dose of ICRF-159 for extended periods is more effective in enhancing radiotherapy than a high dose provided acutely.
THE cancer-chemotherapeutic agent ICRF-159 [(i)1,2-di (3,5-dioxopiperazine-1-yl) propane] belongs to a family of bisdioxopiperazines which has been reported as cytotoxic during a brief period of the cell cycle . Using PHA-stimulated human lymphocytes (Sharpe et al., 1970) and erythroid maturation in C57BL mice (Blackett & Adams, 1972) , ICRF-159 was found to prevent the entrance of cells into mitosis if the cells were exposed during the premitotic and early mitotic (G2/M) phases of the cell cycle. Furthermore, drug cytotoxicity has been reported to be scheduledependent rather than dose-dependent (Hallowes et al., 1974; Stephens & Creighton, 1974) . Taylor & Bleehen (1977a) have recently reported that prolonged exposure to low concentrations of ICRF-159 are more lethal to the EMT6 tumour-cell line than high concentrations. This dose response has been attributed to the cytostatic action of the drug at high concentrations.
In addition to cytotoxicity, has been reported to function as (1) an antimetastatic agent (Hellman & Burrage, 1969; Salsbury et at., 1970) and (2) as a radiopotentiator (Hellmann & Murken, 1974; Norpoth et al., 1974; Peters, 1976; Ryall et al., 1974) . Both the antimetastatic and radiopotentiating activities of ICRF-159 have been attributed to a drug-induced angiometamorphic effect found in studies on the Lewis lung carcinoma (LL) (LeServe & Hellmann, 1972; James & Salsbury, 1974; Salsburyetal., 1974) . However, Peters (1976) , studying the modifying effects of ICRF-159 on clamped tumours suggests that improved vascularization can not fully explain the drug's "radiosensitizing" action. Furthermore, Taylor & Bleehen (1977a, b) (Fig. 3) . Tumours pretreated for 7 days before irradiation, however, showed an enhanced response to 600 rad (see Fig. 1 ). With drug pretreatment, 100 mg/kg dose. Similarly, the tumours receiving 175 mg/kg appeared slightly larger than control for a short time. However, there was little significant difference in size of tumours on Day 20 post inoculum between any of the groups. Acute treatment with ICRF-159 up to 175 mg/kg had little effect on the growth rate of tumours, when compared to daily injections of 25 mg/kg. After 600 rad X-rays, LL regressed within 24 h, and continued to shrink over the next 24 h. Regrowth was apparent 3-4 days after radiation (dashed lines, with drug+radiation reinitiated growth more rapidly than after radiation alone.
To determine whether the drug carrier (CMC-saline) protected the tumour against radiation, the 100 mg/kg ICRF-159 experiment was repeated and a comparison was made between the tumour response to radiation after both ICRF-159 in CMCsaline and CMC-saline-alone pretreatments. This comparison is summarized in Fig. 6 . Pretreatment with CMC-saline alone failed to alter the course of radiationinduced regression and regrowth. However, pretreatment with ICRF-159 in CMC-saline diminished the radiation effect much as in Fig. 5 . Fractionated ICRF-159 treatments: drugschedule effects on the radiation response
The tumour response to radiation after pretreatment with 25 mg/kg ICRF-159 at 3 h intervals is presented in Fig. 7 . Tumours receiving 4 and 3 injections (total dose 100 and 75 mg/kg respectively) before irradiation showed significantly more radiation-induced regression of LL than tumours receiving 1 and 2 injections (25 and 50 mg/kg) before irradiation. The differences between the groups receiving 3 or 4 injections and those receiving 1 or 2 injections suggest that pretreatment drug efficacy may be related to dose level (50-75 mg/kg) and/or total length of protracted treatment (6-9 h). The increased efficacy of fractionated pretreatment with ICRF-159 before radiation over acutely administered drug+ radiation is seen in Fig. 8 (Denekamp, 1972; Kovacs et al., 1977) , tumour regression and the accompanying regrowth delay, as seen in Fig. 8 , demonstrate the superiority of fractionated over acute pretreatment with ICRF-159 before radiotherapy. Pretreatments were completed 3 h before irradiation.
DISCUSSION
Several reports have suggested that multiple treatments with ICRF-159 inhibited the growth of the LL, although the degree of inhibition ranged from negligible to highly effective (Hellmann & Burrage, 1969; Salsbury, 1970; James & Salsbury, 1974) . The results in our present studies (Figs. 2 & 3) , as well as those reported for other experimental tumours (Hellmann & Murken, 1974; Norpoth et al., 1974; Atherton, 1975) is a reduction in growth fraction and elongation of mean cycle time. Our data therefore suggest that the LL tumour, most sensitive to ICRF-159-induced kinetic and growth perturbations when combined with radiation, would be a highly proliferative tumour. Stanley et al. (1977) have demonstrated a tumour-size dependence on therapeutic sensitivity of LL, and have suggested that a change in radiosensitivity can be attributed to a marked increase in the hypoxic fraction, correlated with increased necrotic and haemorrhagic areas.
Although Hellmann & Murken (1974) have experimental evidence that ICRF-159 potentiated radiation effects, and have postulated that the synergism of drug and radiation might be closely linked to the normalization of tumour blood vessels, reducing tumour hypoxia, from the studies presented in Fig. 3 (Fig. 3 ) when compared to daily treatment at lower doses (Fig. 2) , suggesting that drug exposure time rather than dose determines drug efficacy. and Sharpe et al. (1970) have reported that the cytotoxic effect of ICRF-159 was limited to a very brief period (G2/M) of the cell cycle, and that for short incubations cell kill was independent of dose. In addition to the cytotoxic effect, ICRF-159 can act concomitantly as a cytostatic agent, preventing cells from entering mitosis (Hallowes et al., 1974; Blackett & Adams, 1972) . Recently, Taylor & Bleehen (1977a) have shown that the manifestations of cytotoxicity are dependent on both drug exposure time and drug concentration. While low concentrations were equally as effective as high doses initially in terms of cell kill, non-cytostatic concentrations (10 ,ug/ml) produced progressive cell kill, but only during prolonged drug exposure. Single injections of ICRF-159 (25-175 mg/kg) at the time of irradiation, unlike daily pretreatment with the drug, failed to potentiate the radiation response of LL (Fig. 4) . In fact, there is some evidence that the drug "protected" against radiation; regrowth ofdrug+irradiation-treated tumours began earlier than tumours treated with radiation alone. Similar differences have also been reported for the radiosensitivity of cells in vitro after acute (Hellmann & Murken, 1974) and protracted (Taylor & Bleehen, 1977a) pretreatment with ICRF-159. Acute drug pretreatment failed to enhance the radiosensitivity of cells. Protracted drug exposure, however, significantly decreased the width of the shoulder of the radiation survival curve provided that drug exposure before irradiation was longer than 10 h. From their studies, Taylor and Bleehen (1977b) concluded that ICRF-159 prevents cells from accumulating sublethal damage rather than preventing the repair of such damage. Norpoth et al. (1974) have reported that the carboxymethyl cellulose (CMC) drug carrier protected the Walker 256 carcinosarcoma against the effects of radiation. Our studies (Fig. 5) , however, failed to demonstrate any protective effect of CMC on the radiation response of the LL tumour.
It seems clear that fractionated pretreatment with ICRF-159 is better than acute pretreatment for potentiating radiotherapy. Whether this distinction results from the maintenance of a threshold dose over extended periods, or from a cumulative dose, is at this point unknown. Also, the mechanism of such potentiation of the radiation effect is unknown, but most probably is cytokinetic in nature. The enhanced radiation response after fractionated pretreatment could be the result of either (1) a drug-induced redistribution or synchrony at G2/M; (2) a reduced potential for the accumulation and/or repair of sublethal radiation damage; or (3) a combination of (1) and (2).
Both daily and fractionated pretreatments with ICRF-159 increased the efficacy of combined drug+radiation therapy. Whether the mechanism responsible for the enhancement is the same under both pretreatment conditions is not clear. It is likely that mechanisms other than vascular normalization are operative in short intervals after ICRF-159 administration.
